Komori
OncoTherapy Science (4564) · InitiativeDropped

Continuation of the response plan for large-scale purchases

First written in FY2016. 9 of 13 entries say "Restated". Latest entry: FY2024.

13entries
9years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY2018-Q3AdvancedFY2018RestatedFY2020-Q1 – FY2020-Q3AdvancedFY20222016: 320162017: 320172018: 220182019: 220192020: 120202021: 020212022: 120222023: 020232024: 12024
Same theme, other companies
Non-Renewal and Abolition of Takeover Defense MeasuresA theme 51 companies write about · 0 as a headwind · 2 as a tailwind

The whole theme swung hardest in 2023: 1 of 6 companies on the "Worse" side.

35 other companies' latest entry also says "Dropped".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 51 companies compared. The sentences above are computed from all 51.
Full recordFilings, disclosures and news, newest first
  1. FY2024DroppedAnnual report

    「At a meeting of the Board of Directors held on 22 April 2024, the company resolved not to renew the plan upon the conclusion of the annual general meeting of shareholders.」

    The company resolved not to renew, upon the conclusion of the annual general meeting of shareholders to be held in June 2024, the takeover defense measures that had been continued to cover large-scale purchases of 20% or more.
  2. FY2022AdvancedAnnual report

    「The resolution was approved at the 20th annual general meeting of shareholders held on 22 June 2021. The plan's effective period was stipulated to run from the conclusion of the annual general meeting of shareholders for the fiscal year ended March 2021 to the conclusion of the annual general meeting of shareholders scheduled to be held in June 2024.」

    Continuation of the measures against large-scale purchases was approved at the annual general meeting of shareholders in June 2021, and the effective period was extended through the conclusion of the annual general meeting of shareholders scheduled to be held in June 2024.
  3. FY2020-Q3RestatedAnnual report

    「The plan's effective period was stipulated to run from the conclusion of the annual general meeting of shareholders for the fiscal year ended March 2018 to the conclusion of the annual general meeting of shareholders scheduled to be held in June 2021.」

    The company continues the measures covering large-scale purchases of 20% or more through the conclusion of the annual general meeting of shareholders scheduled to be held in June 2021.
  4. FY2020-Q2RestatedAnnual report

    「The plan's effective period was stipulated to run from the conclusion of the annual general meeting of shareholders for the fiscal year ended March 2018 to the conclusion of the annual general meeting of shareholders scheduled to be held in June 2021.」

    The company continues the measures covering large-scale purchases of 20% or more through the conclusion of the annual general meeting of shareholders scheduled to be held in June 2021.
  5. FY2020-Q1RestatedAnnual report

    「a. Purchases of shares issued by the company that would result in the purchaser's shareholding ratio reaching 20% or more The plan's effective period was stipulated to run from the conclusion of the annual general meeting of shareholders for the fiscal year ended March 2018 to the conclusion of the annual general meeting of shareholders scheduled to be held in June 2021.」

    The company continues the measures covering large-scale purchases of 20% or more, with an effective period through the conclusion of the annual general meeting of shareholders scheduled to be held in June 2021.
  6. FY2018AdvancedAnnual report

    「At a meeting of the Board of Directors on 23 May 2018, the company resolved to continue implementing the measures without major changes to their substance, and the resolution was approved at the general meeting of shareholders held on 22 June 2018.」

    The continuation of the measures against large-scale purchases was approved at the general meeting of shareholders, and the effective period was extended from June 2018 to the conclusion of the annual general meeting of shareholders scheduled to be held in June 2021.
  7. FY2018-Q3RestatedAnnual report

    「a. Purchases of shares issued by the company that would result in the purchaser's shareholding ratio reaching 20% or more The plan's effective period was stipulated to run from the conclusion of the annual general meeting of shareholders for the fiscal year ended March 2015 to the conclusion of the annual general meeting of shareholders scheduled to be held in June 2018.」

    The company continues the takeover defense measures covering large-scale purchases of 20% or more, with the measures effective through June 2018.
  8. FY2018-Q2RestatedAnnual report

    「a. Purchases of shares issued by the company that would result in the purchaser's shareholding ratio reaching 20% or more」

    The company continues the measures covering large-scale purchases of 20% or more, with an effective period through the conclusion of the annual general meeting of shareholders scheduled to be held in June 2018.
  9. FY2017RestatedAnnual report

    「The plan's effective period was stipulated to run from the conclusion of the annual general meeting of shareholders for the fiscal year ended March 2015 to the conclusion of the annual general meeting of shareholders scheduled to be held in June 2018.」

    The company continues the takeover defense measures covering large-scale purchases of 20% or more, with an effective period through June 2018.
  10. FY2017-Q3RestatedAnnual report

    「a. Purchases of shares issued by the company that would result in the purchaser's shareholding ratio reaching 20% or more The plan's effective period was stipulated to run from the conclusion of the annual general meeting of shareholders for the fiscal year ended March 2015 to the conclusion of the annual general meeting of shareholders scheduled to be held in June 2018.」

    The company continues the takeover defense measures covering large-scale purchases of 20% or more, with the measures effective through June 2018.
  11. FY2017-Q2RestatedAnnual report

    「a. Purchases of shares issued by the company that would result in the purchaser's shareholding ratio reaching 20% or more The plan's effective period was stipulated to run from the conclusion of the annual general meeting of shareholders for the fiscal year ended March 2015 to the conclusion of the annual general meeting of shareholders scheduled to be held in June 2018.」

    The company has reproduced, without changes to their substance, the measures covering large-scale purchases of 20% or more and the effective period through June 2018.
  12. FY2017-Q1RestatedAnnual report

    「The plan's effective period was stipulated to run from the conclusion of the annual general meeting of shareholders for the fiscal year ended March 2015 to the conclusion of the annual general meeting of shareholders scheduled to be held in June 2018.」

    The company continues the measures against large-scale purchases without major changes to their substance.
  13. FY2016First statedAnnual report

    「The plan's effective period was stipulated to run from the conclusion of the annual general meeting of shareholders for the fiscal year ended March 2015 to the conclusion of the annual general meeting of shareholders scheduled to be held in June 2018.」

    The measures apply to purchases that would result in the purchaser's shareholding ratio, or the total shareholding ratio following a tender offer, reaching 20% or more, and establish procedures involving an independent committee and the gratis allotment of share acquisition rights, among others.
Moved together

"Significant expansion of revenue and profit through drug launches and stabilization of the revenue base" moved the same way as this thread, in the same document, in 2 of its 13 moves.

222★123
  1. ★This thread
  2. 1Significant expansion of revenue and profit through drug launches and stabilization of the revenue base2×
  3. 2Establishment of Cancer Precision Medicine (CPM) and expansion of genomic analysis and cancer immunology businesses through a joint venture with TE2×
  4. 3Securing and utilizing the patent portfolio2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for OncoTherapy Science yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Continuation of the response plan for large-scale purchases | OncoTherapy Science,Inc. (4564) | Komori